Legend Biotech(LEGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LEGN Legend Biotech

Market Closed 04-02 16:00:00 EDT

19.14

+0.09

+0.47%

盘后19.14

+0.000.00%

16:10 EDT

High19.36	Low18.72	Vol1.24M
Open18.98	D1 Closing19.05	Amplitude3.36%
Mkt Cap3.53B	Tradable Cap1.56B	Total Shares184.69M
T/O23.57M	T/O Rate1.52%	Tradable Shares81.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"Legend Biotech","latestPrice":19.14,"timestamp":1775160000000,"preClose":19.05,"halted":0,"volume":1237424,"hourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"16:10 EDT","volume":6974,"amount":133482.36,"timestamp":1775160604510,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00472440944881889,"floatShares":81382003,"shares":184689564,"eps":-1.62,"marketStatus":"Market Closed","change":0.09,"latestTime":"04-02 16:00:00 EDT","open":18.98,"high":19.36,"low":18.72,"amount":23567849.063994,"amplitude":0.033596,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.62,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":2,"listingDate":1591329600000,"exchange":"NASDAQ","adjPreClose":19.05,"preHourTrading":{"tag":"盘前","latestPrice":18.97,"preClose":19.05,"latestTime":"09:29 EDT","volume":2755,"amount":51900.42565,"timestamp":1775136541110,"change":-0.08,"changeRate":-0.004199,"amplitude":0.029396},"postHourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"16:10 EDT","volume":6974,"amount":133482.36,"timestamp":1775160604510,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9313892408099792,"impliedVol":0.541,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/LEGN/wiki","defaultTab":"wiki","newsList":[{"id":"2624821636","title":"Legend Biotech Earnings Call Highlights CARVYKTI Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2624821636","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624821636?lang=en_us&edition=fundamental","pubTime":"2026-04-03 08:24","pubTimestamp":1775175897,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation (($LEGN)) has held its Q4 earnings call. Read on for the main highlights of the call. Legend Biotech’s latest earnings c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legend-biotech-earnings-call-highlights-carvykti-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legend-biotech-earnings-call-highlights-carvykti-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624522309","title":"Is Legend Biotech (LEGN) Pricing Reflect Its Value After Recent Share Price Rebound?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624522309","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624522309?lang=en_us&edition=fundamental","pubTime":"2026-04-02 11:35","pubTimestamp":1775100932,"startTime":"0","endTime":"0","summary":"If you are wondering whether Legend Biotech's share price reflects its underlying value, this article breaks down what the current market price may be implying about the company.\nThe stock closed at US$19.05, with returns of 8.2% over the last week and 3.3% over the last month. The 1 year return stands at a 42.7% decline and the 3 year return at a 60.5% decline.\nRecent coverage around Legend Biotech has focused on its position in the biotech space and how investors are reassessing risk and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-legend-biotech-legn-pricing-reflect-its-value-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-legend-biotech-legn-pricing-reflect-its-value-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4581","XBI","BK4505","BK4585","LEGN","BK4588","DCF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623360665","title":"Legend Biotech Corp : Piper Sandler Cuts Target Price to $64 From $78","url":"https://stock-news.laohu8.com/highlight/detail?id=2623360665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623360665?lang=en_us&edition=fundamental","pubTime":"2026-03-30 11:22","pubTimestamp":1774840938,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40F0FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","BK4585","LEGN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622802668","title":"Legend Biotech CEO Makes Notable Insider Move in Latest Stock Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2622802668","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622802668?lang=en_us&edition=fundamental","pubTime":"2026-03-28 10:03","pubTimestamp":1774663412,"startTime":"0","endTime":"0","summary":"New insider activity at Legend Biotech ( ($LEGN) ) has taken place on March 27, 2026. Legend Biotech’s Chief Executive Officer, Ying Huang, recentl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/legend-biotech-ceo-makes-notable-insider-move-in-latest-stock-transaction-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/legend-biotech-ceo-makes-notable-insider-move-in-latest-stock-transaction-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","LEGN","BK4585","BK4505","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622804136","title":"J&J Exits 3 Biotechs, Retains Stakes in 2 Possible Acquisitions -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2622804136","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622804136?lang=en_us&edition=fundamental","pubTime":"2026-03-28 09:31","pubTimestamp":1774661460,"startTime":"0","endTime":"0","summary":"Johnson & Johnson's restated fourth-quarter holdings report, filed last week, reveals that the company exited three biotechs while retaining its stakes in several rumored acquisition targets.The changes included the sale of 247,598 shares in Arrowhead Pharmaceuticals, previously a partner of Johnson & Johnson's Janssen unit, which rebranded as its Innovative Medicine division. The relationship came to an end in 2023 after Janssen shrunk its infectious disease and vaccine portfolios.Johnson & Johnson also exited BiomX, another former collaborator, through the sale of 96,866 shares. The Israeli biotech in December suddenly halted its lead clinical program due to safety concerns, and has been restructuring since.Also in the fourth quarter, Johnson & Johnson unloaded 54,621 shares of Senseonics Holdings to close out its stake in the medical technology maker.Other holdings went unchanged, including Johnson & Johnson's stake of 814,586 shares in Legend Biotech. The companies have an agreemen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","LU0466842654.USD","LU1280957306.USD","LU0787776722.HKD","SG9999002232.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU2602419157.SGD","LU0640476718.USD","LU1430594728.SGD","IE00BKVL7J92.USD","LU2129689605.HKD","LU0122379950.USD","BK4533","LU0345770308.USD","LEGN","LU0289739699.SGD","LU1059921491.USD","LU1267930813.SGD","IE0001KFT4U8.USD","LU2129689431.USD","IE00B19Z3581.USD","LU2471134523.USD","LU0124676726.USD","PTGX","LU2129689514.USD","ARWR","LU1023059063.AUD","IE00BLSP4452.SGD","LU0985320562.USD","LU2471134796.USD","LU0345770993.USD","LU2089984988.USD","JNJ","LU0689626769.HKD","LU1732799900.SGD","LU0058720904.USD","LU1674673428.USD","LU1196500208.SGD","BK4581","BK4504","IE00BBT3K403.USD","PHGE","LU1244550494.USD","IE00BLSP4239.USD","IE00BFTCPJ56.SGD","LU2592432038.USD","LU1929549753.HKD","LU0203345920.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620295441","title":"Legend Biotech director Tomas J. Heyman files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620295441","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620295441?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:05","pubTimestamp":1773875120,"startTime":"0","endTime":"0","summary":"Legend Biotech reported an initial statement of beneficial ownership by director Tomas Heyman. The filing listed 32,734 ordinary shares beneficially owned. It also reported a share option for 30,000 ordinary shares with an exercise price of USD 23.27.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2nwHkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","LEGN","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620954892","title":"Legend Biotech files Form 3 as director Meng Robin reports no beneficial ownership securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620954892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620954892?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:03","pubTimestamp":1773875014,"startTime":"0","endTime":"0","summary":"Legend Biotech reported that director Robin Meng filed an initial statement of beneficial ownership. The filing listed no securities as beneficially owned by Robin Meng. The date of the event requiring the statement was 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL73sy7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4588","BK4139","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620143295","title":"Legend Biotech director Casey Patrick John files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620143295","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620143295?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:00","pubTimestamp":1773874841,"startTime":"0","endTime":"0","summary":"Legend Biotech reported an initial statement of beneficial ownership for director Casey Patrick John. The filing lists 54,604 ordinary shares beneficially owned directly. It also reports a directly held option for 30,000 ordinary shares with an exercise price of USD 14.12. The option expires on 03/28/2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL695BwD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4139","BK4588","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620295667","title":"Legend Biotech CFO Carlos E Santos Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620295667","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620295667?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:53","pubTimestamp":1773874414,"startTime":"0","endTime":"0","summary":"Legend Biotech reported an initial statement of beneficial ownership for Carlos Santos, its chief financial officer. The filing stated that Carlos Santos beneficially owned no securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8HMjd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4139","BK4588","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620829569","title":"Legend Biotech Director Corazon D. Sanders Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620829569","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620829569?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:52","pubTimestamp":1773874323,"startTime":"0","endTime":"0","summary":"Legend Biotech reported an initial statement of beneficial ownership for director Corazon Sanders. Sanders beneficially owned 59,115 ordinary shares. Sanders also held options to buy 12,000 ordinary shares at USD 12 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbkm2lt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LEGN","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620329566","title":"Legend Biotech CEO and Director Huang Ying files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620329566","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620329566?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:50","pubTimestamp":1773874250,"startTime":"0","endTime":"0","summary":"Legend Biotech reported an initial statement of beneficial ownership for Huang Ying, a director and chief executive officer. Huang beneficially owned 257,374 ordinary shares. The filing also reported share options covering 81,788 ordinary shares at an exercise price of USD 1.5. It also reported share options covering 185,340 ordinary shares at an exercise price of USD 27.5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5dXpyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LEGN","BK4505","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620629563","title":"Legend Biotech files Form 3 initial beneficial ownership statement for director Wang Ye","url":"https://stock-news.laohu8.com/highlight/detail?id=2620629563","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620629563?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:49","pubTimestamp":1773874167,"startTime":"0","endTime":"0","summary":"Legend Biotech reported that director Wang Ye filed an initial statement of beneficial ownership dated 03/18/2026. Wang Ye reported beneficial ownership of 16 ordinary shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL60fFZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4139","LEGN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122455261","title":"GENSCRIPT BIO (01548) Surges Over 5% on Strong Annual Revenue Growth and Narrowed Losses at Legend Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1122455261","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122455261?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:23","pubTimestamp":1773717798,"startTime":"0","endTime":"0","summary":"GENSCRIPT BIO (01548) saw its shares rise more than 5% in Hong Kong trading. At the time of writing, the stock was up 3.24%, trading at HKD 66.95, with a turnover of HKD 62.81 million. The movement...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4585","BK4588","HK0000306685.HKD","HK0000306701.USD","HK0000320264.USD","VXUS","LEGN","BK1576","BK1141","BK4139","01548","BK4505","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619154022","title":"Legend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated","url":"https://stock-news.laohu8.com/highlight/detail?id=2619154022","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619154022?lang=en_us&edition=fundamental","pubTime":"2026-03-13 10:31","pubTimestamp":1773369104,"startTime":"0","endTime":"0","summary":"In March 2026, Legend Biotech reported fourth-quarter 2025 revenue of US$306.3 million, up from US$186.5 million a year earlier, with an adjusted profit of US$0.01 per share but a GAAP net loss of US$30.9 million for the quarter and US$296.8 million for the full year on revenue of US$1.03 billion.\nThe company’s CARVYKTI franchise reached more than 10,000 treated patients, achieved product-level profitability in 2025, and expanded to 294 treatment sites across 14 markets while scaling...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","BK4585","XBI","BK4587","BK4023","AI","AIYY","LEGN","BK4543","BK4528","BK4581","BK4551","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618295009","title":"Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2618295009","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618295009?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:30","pubTimestamp":1773243018,"startTime":"0","endTime":"0","summary":"Legend Biotech  shares should rebound in 2026 on robust execution of Carvykti to treat multiple myeloma, improving real-world safety and manufacturing expansion, RBC Capital Markets said in a note Tuesday.Shares have declined due to market sentiment that there are limited catalysts amid rising competition. However, the brokerage said it thinks threats will fail to materialize and that competitive threats are overstated.RBC said it expects profitability in 2026 as Carvykti expands into earlier lines and community practices due to the rapid adoption driven by \"remarkable\" single-dose efficacy.The analysts projected $2.80 billion worth of Carvykti sales in 2026 and $8 billion in peak sales. For Q1, it expects incremental sales growth due to seasonal trends like patients treatment timing preferences and insurance plan transfers in the new calendar years, the analysts said.Carvykti's franchise profitability is also likely to sustain through 2026, while a strong cash position creates flexibi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XBI","BK4505","LEGN","BK4585","BK4588","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618256909","title":"Legend Biotech Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618256909","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618256909?lang=en_us&edition=fundamental","pubTime":"2026-03-11 22:29","pubTimestamp":1773239340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LEGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 10:29 ET (14:29 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618775940","title":"Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618775940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618775940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:10","pubTimestamp":1773234604,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN – Research Report) and Medtro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-legend-biotech-legn-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-legend-biotech-legn-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0208291251.USD","LU1057294990.SGD","LU0320765489.SGD","IE00BDGV0183.EUR","LU0122379950.USD","BK4566","LU0976567544.SGD","LU1989771016.USD","LU0070302665.USD","LU0432979614.USD","IE00B3PB1722.GBP","LEGN","XLV","LU1116320737.USD","BK4137","LU0029874061.USD","LU1571399168.USD","IE00BQXX3C00.GBP","LU1989764664.SGD","LU1061106388.HKD","LU0158827781.USD","IE00BQXX3D17.EUR","LU2468319806.SGD","LU2089284900.SGD","LU0072461881.USD","LU2112291526.USD","HCSG","LU1116320901.HKD","LU1291159041.SGD","MDT","LU2271345857.HKD","LU0211326839.USD","LU1023059063.AUD","LU1244550494.USD","LU2089984988.USD","LU1506573853.SGD","BK4082","BK4505","LU0496365809.HKD","XBI","LU0314106906.USD","LABU","IE00BVYPNV92.GBP","BK4585","LU2028103732.USD","BK4139","LU0128526141.USD","IE00BVYPNW00.USD","IE000M9KFDE8.USD","LU0265550946.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618194032","title":"Legend Biotech price target lowered to $49 from $50 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2618194032","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618194032?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:52","pubTimestamp":1773233570,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Legend Biotech (LEGN) to $49 from $50 and keeps an Overweight rating on the shares. The firm, whi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/legend-biotech-price-target-lowered-to-49-from-50-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/legend-biotech-price-target-lowered-to-49-from-50-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947501","title":"Legend Biotech price target lowered to $62 from $66 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947501","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947501?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:39","pubTimestamp":1773232764,"startTime":"0","endTime":"0","summary":"RBC Capital lowered the firm’s price target on Legend Biotech (LEGN) to $62 from $66 and keeps an Outperform rating on the shares after its Q4 resu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/legend-biotech-price-target-lowered-to-62-from-66-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/legend-biotech-price-target-lowered-to-62-from-66-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618942439","title":"Morgan Stanley Keeps Their Buy Rating on Legend Biotech (LEGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942439","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942439?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:19","pubTimestamp":1773231546,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Buy rating on Legend Biotech today and set a price target of $49.00. Flynn covers the Healthcare ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-legend-biotech-legn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-legend-biotech-legn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LEGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":0.0943},{"period":"1month","weight":0.0717},{"period":"3month","weight":-0.1102},{"period":"6month","weight":-0.403},{"period":"1year","weight":-0.4242},{"period":"ytd","weight":-0.1196}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Legend Biotech Corp is a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's differentiated technology, global development and manufacturing strategy and expertise provide it with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.047546},{"month":2,"riseRate":0.5,"avgChangeRate":0.01776},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.03136},{"month":4,"riseRate":0.833333,"avgChangeRate":0.072485},{"month":5,"riseRate":0.4,"avgChangeRate":0.007649},{"month":6,"riseRate":1,"avgChangeRate":0.150366},{"month":7,"riseRate":0.666667,"avgChangeRate":0.033873},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.05555},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.023313},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.000245},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.020911},{"month":12,"riseRate":0,"avgChangeRate":-0.105244}],"exchange":"NASDAQ","name":"Legend Biotech","nameEN":"Legend Biotech","securityTypeName":"DR","adrRate":"1:2"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Legend Biotech(LEGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Legend Biotech(LEGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Legend Biotech,LEGN,Legend Biotech股票,Legend Biotech股票老虎,Legend Biotech股票老虎国际,Legend Biotech行情,Legend Biotech股票行情,Legend Biotech股价,Legend Biotech股市,Legend Biotech股票价格,Legend Biotech股票交易,Legend Biotech股票购买,Legend Biotech股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Legend Biotech(LEGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Legend Biotech(LEGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}